# Elafibranor Pharmacokinetic Parameters in Renal Impaired Patients

> **NCT03844555** · PHASE1 · COMPLETED · sponsor: **Genfit** · enrollment: 23 (actual)

## Conditions studied

- Renal Impairment
- Renal Insufficiency
- Kidney Diseases
- Pharmacokinetics

## Interventions

- **DRUG:** Elafibranor

## Key facts

- **NCT ID:** NCT03844555
- **Lead sponsor:** Genfit
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-28
- **Primary completion:** 2020-03-15
- **Final completion:** 2020-03-21
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2020-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03844555

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03844555, "Elafibranor Pharmacokinetic Parameters in Renal Impaired Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03844555. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*